Precision active pharmaceutical ingredients are the goal

被引:0
|
作者
Miller, Andrew D. [1 ,2 ]
机构
[1] Kings Coll London, Inst Pharmaceut Sci, Franklin Wilkins Bldg,Waterloo Campus, London SE1 9NH, England
[2] KP Therapeut Ltd, 86 Deansgate, Manchester M3 2ER, Lancs, England
关键词
antisense peptides; chemical biology; chemistry of stress; complementary peptides; diadenosine polyphosphates; dinucleoside polyphosphates; molecular chaperones; precision active pharmaceutical ingredients; precision medicine; synthetic biology; thioether fatty acids; TRANSFER-RNA SYNTHETASE; MITOCHONDRIAL MALATE-DEHYDROGENASE; CHAPERONIN; 60; GROEL; PROTEIN; 47; HSP47; ESCHERICHIA-COLI; DIADENOSINE; 5'; 5'''-P-1; P-4-TETRAPHOSPHATE; CPN60; DINUCLEOSIDE POLYPHOSPHATES; CYTOKINE INTERLEUKIN-1; MOLECULAR CHAPERONES;
D O I
10.4155/fmc-2016-0046
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Understanding and exploiting molecular mechanisms in biology is central to chemical biology. Chemical biology studies of biological macromolecules are now in a perfect continuum with molecular level and nanomolecular level mechanistic studies involving whole organisms. The potential opportunity presented by such studies is the design and creation of genuine precision active pharmaceutical ingredients (APIs; including DNA, siRNA, smaller-molecule bioactives) that demonstrate exceptional levels of disease target-specificity and selectivity. This article covers the best of my personal and collaborative academic research work using an organic chemistry and chemical biology approach towards understanding biological molecular recognition processes, work that appears to be leading to the generation of novel precision APIs with genuine potential for the treatments of major chronic diseases that afflict globally.
引用
收藏
页码:1209 / 1238
页数:30
相关论文
共 50 条
  • [21] A sourcing strategy for active pharmaceutical ingredients (APIs)
    Clarke, GM
    Schnurrenberger, KP
    Scholl, B
    CHIMIA, 1998, 52 (06) : 257 - 259
  • [22] Ionic liquids based active pharmaceutical ingredients
    Singh Sekhon, Bhupinder
    ARS PHARMACEUTICA, 2013, 54 (04) : 38 - 44
  • [23] Stable isotopic characterization of active pharmaceutical ingredients
    Jasper, JP
    Westenberger, BJ
    Spencer, JA
    Buhse, LF
    Nasr, M
    JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2004, 35 (01) : 21 - 30
  • [25] The regulation of highly potent active pharmaceutical ingredients
    Greenwald, S
    Bufano, M
    CHIMICA OGGI-CHEMISTRY TODAY, 2006, 24 (02) : 12 - 14
  • [26] Polymorphism and Crystallization of Active Pharmaceutical Ingredients (APIs)
    Lu, Jie
    Rohani, Sohrab
    CURRENT MEDICINAL CHEMISTRY, 2009, 16 (07) : 884 - 905
  • [27] Active Pharmaceutical Ingredients, Ferments, Vitamins, Hormones
    Franke
    NERVENARZT, 1951, 22 (12): : 464 - 464
  • [28] Heat capacities of selected active pharmaceutical ingredients
    Stejfa, Vojtech
    Pokorny, Vaclav
    Mathers, Alex
    Ruzicka, Kvetoslav
    Fulem, Michal
    JOURNAL OF CHEMICAL THERMODYNAMICS, 2021, 163
  • [29] Impurities in Drug Products and Active Pharmaceutical Ingredients
    Katny, M.
    Frankowski, M.
    CRITICAL REVIEWS IN ANALYTICAL CHEMISTRY, 2017, 47 (03) : 187 - 193
  • [30] PBT/PMT assessment of active pharmaceutical ingredients
    Janer, Gemma
    Elmoznino, Joanne
    Haner, Andreas
    Bramke, Irene
    REGULATORY TOXICOLOGY AND PHARMACOLOGY, 2025, 156